PSMA MRI引导的前列腺SBRT(ARGOS)/放疗后影像生物标志物综合纵向评估(CLIMBER)I/II期试验
ARGOS-CLIMBER是一项多机构I/II期研究,采用18F-PSMA 1007 PET/MRI引导的5次SABR同步整合加量治疗中高危前列腺癌,主要终点为6个月内毒性。50例患者中仅1例急性3级腹泻和1例晚期4级出血,6个月毒性可接受。
要点
- 5次SABR同步整合加量至前列腺中位41.6 Gy,6个月毒性可接受。
- 仅1例急性3级胃肠道腹泻和1例晚期4级胃肠道出血。
- EPIC-26显示泌尿刺激增加,但尿失禁和胃肠道生活质量无差异。
核心结论
- ARGOS-CLIMBER表明,采用5次SABR联合PET/MRI引导的前列腺和淋巴结同步整合加量,6个月毒性可接受。
研究设计与样本
- 多机构I/II期研究,纳入50例不良中危、高危或极高危前列腺癌患者。
- 采用18F-PSMA 1007 PET/MRI定义同步整合加量体积,5次SABR处方剂量:前列腺35 Gy(最大SIB 50 Gy)、精囊25 Gy(最大SIB 50 Gy)、淋巴结25 Gy(最大SIB 35 Gy)。
- 主要终点为治疗6个月内毒性,采用CTCAE 5.0和EPIC-26评估。
主要发现
- 50例患者中,23例不良中危、23例高危、4例极高危;前列腺中位SIB剂量41.6 Gy(IQR 39.3-44.8 Gy),中位1个前列腺内病灶;18例接受淋巴结治疗。
- 出现1例急性3级胃肠道腹泻和1例晚期4级胃肠道出血。
- 中位随访12个月,EPIC-26显示泌尿刺激增加(P < .001),尿失禁无差异(P = .12),胃肠道生活质量无差异(P = .65),激素/性生活质量下降(P < .001和P < .001)。
- 基线至6个月,PSA从15.4(±10.3)降至0.18(±0.40)ng/mL,PET最大SUV从25.5(±19.5)降至4.5(±7.7),MRI PI-RADS最高评分从4.7(±0.6)降至2.9(±1.5)。
临床怎么用
- 对于不良中危至高危前列腺癌,可考虑5次SABR联合PET/MRI引导的前列腺和淋巴结同步整合加量,需注意泌尿刺激和性/激素生活质量下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The ARGOS-CLIMBER trial is a multi-institutional phase 1/2 study utilizing a combined prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/magnetic resonance imaging (MRI) approach to treat dominant intraprostatic lesions and affected lymph nodes in unfavorable intermediate and high-risk prostate cancer using a 5 fraction SABR and simultaneous in-field boost (SIB) technique. Here we report on the primary endpoint of toxicity within 6 months of treatment. METHODS AND MATERIALS: SIB volumes were defined utilizing a PET/MRI acquired using 18F-PSMA 1007. Five fraction SABR was planned to deliver doses (maximum SIB) to the prostate 35 Gy (50 Gy), seminal vesicles 25 Gy (50 Gy), and lymph nodes 25 Gy (35 Gy) while respecting organs at risk. Toxicity and quality of life (QOL) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events 5.0 and Expanded Prostate Cancer Index Composite (EPIC-26) during radiation, at 6 weeks posttreatment, and at 6 months posttreatment. RESULTS: In total, 50 patients were treated, 23 patients had unfavorable intermediate-risk disease, 23 were high risk, and 4 were very high-risk prostate cancer. Median prostate SIB of 41.6 Gy (IQR, 39.3-44.8 Gy) was delivered to a median of 1 intraprostatic lesion. Eighteen patients received nodal treatment. There was a single acute grade 3 gastrointestinal (GI) toxicity of diarrhea and a single late grade 4 GI toxicity of bleeding. With a median follow-up of 12 months, the EPIC-26 scale showed an increase in urinary irritation (P < .001) and no differences for urinary incontinence (P = .12) and GI QOL (P = .65) and a decrease in hormonal/sexual QOL (P < .001 and P < .001). Mean ± SD prostate-specific antigen, maximum standardized uptake value on PET, and maximum MRI Prostate Imaging Reporting and Data System (PIRADS) scores at baseline to 6 months decreased from 15.4 (± 10.3) to 0.18 (± 0.40) ng/mL, 25.5 (± 19.5) to 4.5 (± 7.7), and 4.7 (± 0.6) to 2.9 (± 1.5), respectively. CONCLUSIONS: ARGOS-CLIMBER demonstrated acceptable 6-month toxicity using 5 fraction SABR with PET/MRI directed SIB to the prostate and lymph nodes.
引用
- Ramadan S, Loblaw A, Dhar A, et al. PSMA MRI Guided prOstate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of IMaging BiomarkErs Post Radiotherapy (CLIMBER) Phase I/II Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 40349854. doi:10.1016/j.ijrobp.2025.04.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。